1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-API Insights, 2015

Summary

DelveInsight’s, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-API Insights, 2015,report provides Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer drugs marketed details and API Manufacturers details across the globe along with the location. The report gives the clear idea on the United States Drug Master File (USDMF) and Europe DMF filed by worldwide countries related to the drugs falling under Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer. The Report provides the India and China API Manufactures who are driving the current API Market. DelveInsight’s report also highlights the patent, patent exclusivity information and competitive landscape. The research analysis also presents the global sales forecasts data for the Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer drugs till 2016.
The active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large number of blockbuster drugs going off patent in the coming years. It is going to affect the revenue of the API market as generic drugs occupy the market.
India and China produce a large percentage of a majority of the APIs and intermediates produced in the world currently. The USFDA and EMA have strict guidelines for API manufacturing 'Process Validation: General Principles and Practices'. While countries such as Japan and Singapore are signatories to the ICH Q7 regulation, India and China follow their national GMP guidelines. The efficiency and expertise of Asian contract manufacturers have positioned them in a very strategic space in the global pharmaceutical supply chain, with a vast majority of the APIs and intermediates being sourced from markets such as India and China.
Data Sources
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

• A snapshot of the global Market therapeutics scenario for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer.
• A review of the marketed products under prescription for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, regulatory information and marketing status.
• Coverage of global patent coverage and detailed commentaries on the US patent challenges.
• Graphical representation of investigational products for patent expiry and market exclusivities across the globe.
• Product profiles for marketed products for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details.
• Coverage of API Manufacturers for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer drugs in the United States, Europe and Asian Regions with location details.
• Coverage of Regulatory filings in the US, Europe, and Asia specifically India and China for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer drugs.
• Key discontinued Marketed products.
• Global Sales Figure from 2012-2016.

Reasons to Buy

• Evaluate the marketing status and exclusivity details of Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer key products to exploit opportunities for generic drug development opportunities.
• Key players in the pharmaceutical industry.
•Strategic drivers and restraints of this market are revealed and market opportunities and challenges are identified.
• Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer.
• API intelligence over marketed drugs for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and gaining primary intelligence over active ingredients manufacturers across the globe.
• Uncovering opportunities in the rapidly growing the US markets.

Table Of Contents

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-API Insights, 2015
Table of Contents
• Indication Overview
• Marketed Drugs Assessment
• Marketed Details of Drugs by Application Type
• Marketed Details of Drugs (NDA) by Marketing Status
• Marketed Details of Drugs by Patent Expiration Timeline
• The Active Pharmaceutical Ingredient (API) Manufacturers Assessment
• The API Manufacturers by the United States Drug Master File (US DMF) Status
• The API Manufacturers by the US DMF Status (Drug Specific)
• Drugs Market Data and Forecasted Sales Figures (2012-2016)
• Marketed Drugs Information
• Drugs Description
• Global Active Pharmaceutical Manufacturers
• Approval Status
• Patent and Exclusivity Details
• Company Overview
• Discontinued Drugs Information

List of Tables

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutic Market, US, Marketed Drugs by Application Type, 2015
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutic Market, US, Marketed Drugs by Marketing Status, 2015
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutic Market, US, (Year), 2015
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Marketed Drugs, API Manufacturers by US DMF Status, 2015
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Marketed Drugs, US DMF Status Drug Specific (Number), 2015
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutic Market, Global Sales (in million USD), 2015
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Marketed Drugs, API Manufacturers, Global, 2015
Discontinued Drugs for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, 2015

List of Figures

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutic Market, US, Marketed Drugs by Application Type (%), 2015
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutic Market, US, Marketed Drugs by Marketing Status (%), 2015
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutic Market, US, (Year), 2015
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Marketed Drugs, API Manufacturers by US DMF Status (%), 2015
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Marketed Drugs, US DMF Status Drug Specific (Number), 2015
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutic Market, Global Sales (in million USD), 2015
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Marketed Drugs, Patent/Exclusivity Expiry (Year), 2015

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Europe Tumor Marker Testing in 28 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppl

2016 Europe Tumor Marker Testing in 28 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppl

  • $ 34500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 28-country survey from VPGMarketResearch.com contains over 925 pages and 366 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...


Download Unlimited Documents from Trusted Public Sources

Related Market Segments :

Hormone

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.